<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03475888</url>
  </required_header>
  <id_info>
    <org_study_id>NL59827.078.16</org_study_id>
    <nct_id>NCT03475888</nct_id>
  </id_info>
  <brief_title>Incidence of Ventricular Arrhythmias in Patients With Chronic Total Occlusion Recanalization</brief_title>
  <acronym>VACTOR</acronym>
  <official_title>Incidence of Ventricular Arrhythmias in Patients With Chronic Total Occlusion Recanalization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A chronic total occlusion (CTO) is common in patients with coronary artery disease. CTO&#xD;
      recanalization has been shown to improve survival in comparison to failed CTO recanalization.&#xD;
      Whether this is related to ventricular arrhythmias (VA) is unknown. The purpose of this pilot&#xD;
      study is to evaluate the incidence of VA after successful CTO recanalization, failed CTO&#xD;
      recanalization and untreated CTO. Patients will be monitored using an insertable cardiac&#xD;
      monitor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Successful chronic total occlusion (CTO) recanalization has been associated with&#xD;
      improved long-term survival. Furthermore, CTO is an independent predictor for the occurrence&#xD;
      of ventricular arrhythmias (VA) in patients with ischemic cardiomyopathy and implantable&#xD;
      cardioverter defibrillators (ICDs). One may speculate that a successful CTO recanalization&#xD;
      may provide electrical stability. However, no data are available on the incidence of&#xD;
      sustained VA in this patient population.&#xD;
&#xD;
      Objective: The objective of the present pilot study is to assess the incidence of sustained&#xD;
      VA in 3 CTO groups: patients with successful percutaneous CTO recanalization (group A),&#xD;
      patients with failed percutaneous CTO recanalization (group B), and patients with untreated&#xD;
      CTO (group C).&#xD;
&#xD;
      Study design: Three-arm pilot study of patients with CTO.&#xD;
&#xD;
      Study population: A total of 90 patients will be enrolled. Intervention: A Medtronic Reveal&#xD;
      LINQ™ Insertable cardiac monitor (ICM) will be implanted in every patient to continuously&#xD;
      monitor heart rhythm during the follow-up period.&#xD;
&#xD;
      Main study parameters/endpoints: To assess the incidence of VA defined as sustained&#xD;
      ventricular tachycardia &gt;30 s or ventricular fibrillation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single center three-arm pilot study of patients with CTO.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventricular Arrhythmias</measure>
    <time_frame>3 years after ICM implantation</time_frame>
    <description>Sustained ventricular tachycardia (&gt;30 s) or ventricular fibrillation</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Chronic Total Occlusion of Coronary Artery</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who have undergone a successful percutaneous CTO recanalization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who have undergone a failed percutaneous CTO recanalization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with an untreated CTO</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Reveal LINQ™ Insertable Cardiac Monitor (ICM)</intervention_name>
    <description>Implantation of Medtronic Reveal LINQ™ ICM</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Presence of CTO defined as complete obstruction of the vessel with Thrombolysis In&#xD;
             Myocardial Infarction (TIMI) flow grade 0 and an estimated duration of ≥3 months, and&#xD;
             one of the following:&#xD;
&#xD;
               1. A successful percutaneous CTO recanalization for stable angina within the&#xD;
                  previous 6 months. A successful CTO recanalization is defined as a final TIMI&#xD;
                  flow grade ≥2 and a residual stenosis ≤30% after stent implantation.&#xD;
&#xD;
               2. A failed percutaneous CTO recanalization for stable angina within the previous 6&#xD;
                  months. A failed CTO recanalization is defined as not fulfilling the criteria for&#xD;
                  successful CTO recanalization.&#xD;
&#xD;
               3. Untreated CTO diagnosed in the previous 6 months.&#xD;
&#xD;
          2. Age ≥18 years.&#xD;
&#xD;
          3. Written informed consent.&#xD;
&#xD;
          4. Patient agrees to the follow-up including the implantation of the ICM.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are potential candidates for an ICD according to the 2015 ESC guidelines.&#xD;
&#xD;
          2. Patients who have a cardiac implantable electrical device (CIED) (e.g., pacemaker,&#xD;
             ICD).&#xD;
&#xD;
          3. Patient has reduced immune function or is otherwise at high risk for infection.&#xD;
&#xD;
          4. Patient has had a recent (within 30 days) or otherwise unresolved infection.&#xD;
&#xD;
          5. Known pregnancy at time of inclusion.&#xD;
&#xD;
          6. Patient has severe co-morbidity that may cause the patient to be non-compliant with&#xD;
             the protocol, confound the data interpretation or is associated with limited life&#xD;
             expectancy (i.e., less than one year).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sing-Chien Yap, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sing-Chien Yap, MD, PhD</last_name>
    <phone>+31 650031551</phone>
    <email>s.c.yap@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amira Assaf, MD</last_name>
    <email>a.assaf@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sing-Chien Yap, MD, PhD</last_name>
      <phone>+31650031551</phone>
      <email>s.c.yap@erasmusmc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2018</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Sing-Chien Yap, MD, PhD</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Chronic Total Occlusion of Coronary Artery</keyword>
  <keyword>Ventricular Arrythmia</keyword>
  <keyword>Sustained VT</keyword>
  <keyword>Ventricular Fibrillation</keyword>
  <keyword>Implantable loop recorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

